Introduction
The hallmark of cancer is a progressive appearance of malignant cell behavior that is triggered by the evolution of altered gene function. Many of the gene changes stem from genetic abnormalities that disrupt coding regions. However, it is becoming clear that epigenetic events, or heritable changes in gene expression capacity without DNA sequence alterations, are also central to tumor progression. The epigenetic control of gene function involves the formation of chromatin that modulates gene transcription. The study of this level of gene control has blossomed over the last decade and is a critical link to our understanding of the neoplastic process.
Chromatin and transcription
Eukaryotic cells must accomplish the daunting task of packaging an enormous amount of DNA into their nucleus, while ensuring the proper expression of a subset of genes and the silencing of other regions of the genome. Higher eukaryotes are especially burdened in this task due to the large amount of repetitive elements (Alu, LINEs, SINEs, etc.) that are scattered throughout their genomes. In general, the genome is compartmentalized into transcriptionally competent euchromatin and transcriptionally incompetent heterochromatin. Cells accomplish this feat by packaging DNA into chromatin, whose basic unit is the nucleosome with *146 bp of DNA wrapped around it. The proper transcriptional status is then achieved through the interplay of protein complexes that associate with, manipulate, and epigenetically modify this basic unit to either foster or inhibit transcription. These epigenetic modi®cations, employing combinations of factors, allow the cell to modulate the transcriptional activity of given gene promoters. In this manner, a rheostat of transcriptional activity provides a range of gene function from high-level expression to complete silencing, as well as setting up gene expression events to react quickly to environmental stimuli.
Two epigenetic modi®cations have emerged as critical layers of regulation that participate in this transcriptional rheostat (Figure 1 ). The ®rst, histone acetylation appears to be used by all eukaryotes as one layer of transcriptional control (Grunstein, 1997) . The acetylation of the amino-terminal tails of histones H3 and H4 by histone acetyltransferases (HATs) creates an accessible chromatin con®guration that facilitates transcriptional activity. Removal of these acetyl groups by histone deacetylases (HDACs) facilitates chromatin compaction that is detrimental to transcription. The cell uses these HATs and HDACs as coactivators and corepressors respectively to modulate promoter activity.
The second epigenetic modi®cation, DNA methylation, has a long-standing relationship with gene inactivity and has been implicated as a critical layer of control for enhancing transcriptional silencing (Bird, 1992; Eden and Cedar, 1994) . However, the lack of such an epigenetic modi®cation in some favorite model organisms (e.g. S. cerevisiae, C. elegans) has long raised questions about the importance of DNA methylation for gene control in eukaryotes. Interestingly, while Drosophila was long thought not to have DNA methylation, recent reports have identi®ed genes with homology to the vertebrate DNA methylation machinery (Tweedie et al., 1999; Hung et al., 1999; Roder et al., 2000; Lyko et al., 2000a) . In addition, trace amounts of cytosine methylation have been detected in this organism (Gowher et al., 2000; Lyko et al., 2000b) .
In mammals, genomic methylation patterns are established during embryogenesis through the interplay of at least three DNA methyltransferases (Dnmt1, Dnmt3a, and Dnmt3b; Figure 2 ) and presumably the factors that associate with these enzymes to target and regulate their enzymatic activity. All three enzymes are essential for proper murine development (Li et al., 1992; Okano et al., 1999) . It has been proposed that the newly identi®ed Dnmt3a and Dnmt3b enzymes act primarily as de novo methyltransferases to establish methylation patterns during embryogenesis . In contrast, Dnmt1 is thought to maintain these methylation patterns during DNA replication. However, the strict designation of these enzymes as either de novo or maintenance methyltransferases is not yet de®nitive.
The vast majority of CpG dinucleotides (*70%) in mammalian genomes are methylated and reside within repetitive elements (Yoder et al., 1997a) . This methylation is a candidate mechanism for helping to transcriptionally silence these elements and thus, has been proposed to serve as a host defense mechanism to inhibit transposition and perhaps to subdue homologous recombination as well (Bird, 1995; Yoder et al., 1997a; Walsh et al., 1998) . The methylation of cytosines makes them more susceptible to deamination, which has reduced the overall frequency of CpGs in the bulk genome (Bird, 1980) . Conversely, the promoter regions of many genes generally remain free of methylation and therefore less susceptible to deamination. Thus, these promoters have retained the expected frequency of CpG dinucleotides and are referred to as`CpG islands'. Studies of the adenine phosphoribosyltransferase (Aprt) locus have identi®ed a potential mechanism for how CpG islands remain free of methylation in embryonic cells. Three groups demonstrated that the presence of Sp1 binding sites and presumably the trans-acting factor that binds to these sites protects the CpG island of the Aprt gene from methylation (Macleod et al., 1994; Brandeis et al., 1994; Mummaneni et al., 1995 Mummaneni et al., , 1998 . Importantly, while most CpG islands remain free of methylation, those associated with transcriptionally silenced genes on the inactive X-chromosome and silenced alleles of imprinted genes are densely methylated (Brandeis et al., 1993) .
DNA methylation and histone deacetylation: partners in transcriptional repression
DNA methylation appears capable of directly preventing the binding of some transcription factors to their DNA binding sites (Tate and Bird, 1993) . However, the majority of inhibition of transcription in association with DNA methylation appears to occur through complex indirect mechanisms involving changes in chromatin formation. Initial experiments demonstrated that in vitro methylated genes transfected into cells were transcriptionally inactive and assumed a chromatin conformation devoid of nuclease sensitive sites present in active genes (Keshet et al., 1986 subsequent transfection assays demonstrated that in vitro methylated genes are initially transcriptionally active, but after a few hours the DNA is packaged into a chromatin con®guration that inhibits transcription (Buschhausen et al., 1987; Kass et al., 1997) . These results indicate that DNA methylation itself does not interfere with transcription, but rather marks the DNA for establishment of a transcriptionally incompetent chromatin state. However, whether DNA methylation initiates the process in vivo or if methylation is a secondary eect following the formation of transcriptionally inactive chromatin is not clear in most cases. For X-chromosome inactivation and the developmental switch in globin gene expression, methylation appears to be a secondary event but is then required for the proper maintenance of the inactive state (Lock et al., 1987; Enver et al., 1988; Sado et al., 2000) . The mechanism(s) behind how methylation mediates a transcriptionally incompetent chromatin organization are now starting to be understood (Bird and Wole, 1999) . The seminal ®ndings of Adrian Bird and his colleagues provided the central clue to this understanding. They have identi®ed a group of proteins, the methyl-CpG binding domain proteins (MBDs), which preferentially bind to methylated CpGs (Meehan et al., 1989; Lewis et al., 1992; Cross et al., 1997; Hendrich and Bird, 1998) . Several of these MBD proteins (MBD1, MBD2, MBD3, MeCP2) repress transcription partially through the action of HDACs. Such an association was ®rst shown for MeCP2, which complexes with HDAC1 and HDAC2 through a direct interaction with Sin3A (Nan et al., 1998; Jones et al., 1998) . Subsequent work demonstrated that MBD3 and/or MBD2 are found in the Mi2/NuRD (nucleosome remodeling histone deacetylase) complex that not only contains HDAC1 and HDAC2 but also Mi-2, a member of the SWI2/SNF2 family of ATP-dependent chromatin remodeling proteins Wade et al., 1999) . MBD2, along with HDAC1 and HDAC2, is also a member of the MeCP1 complex, which was ®rst identi®ed as a methyl-binding activity that required at least 12 symmetrically methylated CpGs for binding in vitro . The speci®c HDAC(s) that associate with MBD1 or any other protein partners have not been reported to date . The direct linkage between the MBDs, HDACs and chromatin remodeling machinery has provided a basis for understanding how DNA methylation can mediate a transcriptionally incompetent chromatin state. However, as detailed below recent results found for the DNMTs suggest that these proteins may contribute to transcriptionally incompetent chromatin beyond transferring methyl groups to cytosines. Recent developments suggest that the DNMTs possess functions in addition to or in cooperation with their methyltransferase enzymatic activity. All three DNMT enzymes have C-terminal methytransferase catalytic domains responsible for transferring methyl groups from S-adenosylmethionine to cytosines in CpG dinucleotides, and longer non-catalytic N-terminal portions that presumably function in a regulatory capacity (Figure 2) (Bestor, 2000) .
The N-terminus of DNMT1 contains regions responsible for targeting the enzyme to replication foci (Leonhardt et al., 1992; Chuang et al., 1997; Liu et al., 1998) , as well as for discriminating between unmethylated and hemi-methylated DNA (Bestor, 1992) . Indeed, this enzyme has a 10 ± 40-fold preference for hemimethylated CpGs over unmethylated CpGs (Pradhan et al., 1997 (Pradhan et al., , 1999 Yoder et al., 1997b) . This portion of DNMT1 also contains a cysteine-rich (CXXC) Zn-binding motif, that resembles motifs found in MBD1 and the human Trithorax proteins (Cross et al., 1997) . Recently, three groups have reported that DNMT1 can repress transcription through its Nterminus, and thus independent of its methylating functions (Fuks et al., 2000; Rountree et al., 2000; . This repression appears to result, in part, through an interaction with HDAC1 and/or HDAC2. In addition, two of these groups identi®ed additional factors that complex with the Nterminus of DNMT1 to perhaps regulate or target the transcriptional repressive and/or methyltransferase activities of this enzyme. found an assortment of proteins that copuri®ed with DNMT1 including retinoblastoma protein (pRB) and E2F. DNMT1 binds to pRB and can be recruited to promoters through and E2F/pRB complex to repress transcription in transient transcription assays. This transcriptional repression did not appear to involve methylation, as methylation was not detected within the promoter. Using the yeast two-hybrid assay, our group identi®ed a novel co-repressor protein, DNMT1 Associated Protein 1 (DMAP1), which binds to the ®rst 120 amino acids of DNMT1 through a coil-coiled domain interaction (Rountree et al., 2000) . In turn, DMAP1 binds Tumor Susceptibility Gene 101 (TSG101), a candidate tumor suppressor gene that is a potent transcriptional co-repressor. Interestingly, through alternative promoter usage the Dnmt1 protein present in oocytes and pre-implantation embryos lack the DMAP1 binding region (Mertineit et al., 1998) . In addition, an alternative isoform of Dnmt1 that lacks the DMAP1 binding region is expressed during muscle dierentiation (Aguirre-Arteta et al., 2000) . Further studies will be required to understand the signi®cance of the DNMT1/DMAP1 interaction and the function of these dierent Dnmt1 isoforms.
The N-termini of DNMT3A and DNMT3B remain relatively uncharacterized in regards to function, but presumably like the N-terminus of DNMT1 serve in a regulatory and/or targeting capacity. The N-termini of both DNMT3A and DNMT3B contain a cysteine-rich, PHD-like ®nger domain that most resembles a domain found in the ATRX protein (Figure 2) (Xie et al., 1999) . However, this cysteine-rich ATRX-like domain does not resemble the cystein-rich CXXC repeats found in the N-terminus of DNMT1. The portion of the DNMT3A and DNMT3B that is N-terminal to the ATRX-like domain diers between the two, and therefore may provide speci®city for the proteins. Similar to DNMT1, we have found that the N-terminal portions of Dnmt3a and Dnmt3b repress transcription in association with HDAC activity (KE Bachman, MR Rountree and SB Baylin; manuscript submitted). This repression and HDAC association is mediated primarily through the ATRX-like domain.
The association of virtually all of the methylation machinery, DNMTs and MBDs, with HDACs provides a cooperative linkage in transcriptional silencing between DNA methylation and histone deacetylation ( Figure 3 ). The challenge now is to understand how these complexes behave within a cell to establish and maintain a repressive state. There are a number of questions to be answered. Do these complexes work in a sequence speci®c manner or is there redundancy in their actions or perhaps they function in dierent cell types? Apart for their anity for a symmetrically methylated CpG, the MBDs have not been shown to possess sequence speci®city. Likewise, the DNMTs have sequence speci®city for CpGs, but no speci®city for the context of this dinucleotide. Therefore, if these complexes do have sequence speci®city it must be via recruitment by another factor. Another possibility is these complexes work in a coordinated manner to continuously insure a transcriptionally incompetent state through the cell cycle. For example, as discussed below, the DNMT1 complex appears to play a crucial role in the maintenance of chromatin during S-phase.
The inheritance of epigenetic states
Every turn of the cell cycle requires a cell to duplicate its genome and to recapitulate the chromatin con®g-uration that existed prior to the passage of the replication fork in order to retain proper genomic Figure 3 The connection between DNA methylation and histone deacetylation. All three of the DNMTs and four of the MBDs repress transcription through an association with HDAC activity Oncogene DNA methylation, chromatin inheritance and cancer MR Rountree et al transcriptional properties. This chromatin assembly entails the proper inheritance of the genomic methylation pattern, reassembly and positioning of nucleosomes, reestablishment of histone modi®cation status, and ®nally reassembly of other chromatin factors that ensure the proper transcriptional status of genes (Kass and Wole, 1996; Krude, 1999) . The cell seems to control the proper inheritance of chromatin states by controlling the spatial organization and timing of replication of dierent portions of its genome . In general, transcriptionally active euchromatin portions of the genome are typically replicated early in S-phase, while transcriptionally inactive heterochromatin tends to replicate later in S-phase.
The proliferating cell nuclear antigen (PCNA), which provides processivity for DNA polymerases during DNA replication, is increasingly recognized as playing a central role in the inheritance of chromatin states through the recruitment of key protein complexes to the DNA. Recent evidence demonstrating that PCNA is critical for the inheritance of heterochromatin regions in yeast supports this notion (Zhang et al., 2000) . Shibahara and Stillman (1999) demonstrated that PCNA is left behind on the DNA following replication and speculate that this may provide a`mark' for the epigenetic inheritance of chromatin states. They further speculate, that this PCNA mark provides a platform to which other proteins bind and reestablish the proper epigenetic states following replication (Shibahara and Stillman, 1999) . Evidence for such a model comes from two key protein complexes that interact with PCNA and play important roles in chromatin formation and epigenetic propagation.
DNMT1 is brought to the replication machinery through a direct interaction with PCNA (Chuang et al., 1997) , and serves to maintain DNA methylation patterns on the daughter strands following passage of the replication fork (Leonhardt et al., 1992; Bestor, 2000) . Work conducted in our laboratory has provided evidence that DNMT1 forms a complex at these replication foci whose constituents change during the course of S-phase (Rountree et al., 2000) . We reported that DMAP1 is recruited through a direct interaction with DNMT1 to replication foci throughout S-phase. However, we found that HDAC2 colocalizes with the DNMT1/DMAP1 complex only during late stages of S-phase. This is potentially extremely important since this is when transcriptionally repressive heterochromatin is replicated.
The other protein complex that binds to PCNA is chromatin assembly factor 1 (CAF-1), which assembles newly synthesized histones H3 and H4 onto the replicated DNA (Shibahara and Stillman, 1999) . Newly synthesized histones are assembled on the DNA with lysine residues 5 and 12 in the acetylated state (Sobel et al., 1995) . The deacetylation of these histones is known to be an essential step in the maturation of heterochromatin (Annunziato and Seale, 1983) . Therefore, the positioning of HDAC2 with the DNMT1/DMAP1 complex late in Sphase is signi®cant because it demonstrates for the ®rst time a plausible mechanism for how newly synthesized nucleosomes become deacetylated following DNA replication. Following maintenance of the repressed epigenetic state of chromatin after replication, the MBD/HDAC complexes could then reassociate with the chromatin and perpetuate the transcriptionally incompetent state through the rest of the cell cycle.
Besides the emerging role of DNMT1 as an important factor in the propagation of epigenetic states during S-phase, the presence of this protein may be required for ecient and timely replication of DNA.
Inhibition of DNMT1 appears to interfere with DNA replication by blocking the activity of replication origins (Knox et al., 2000) . The mechanism for this interference is not clear but suggests that DNMT1 plays an important role in replication initiation. Recently, pRB and E2F were shown to localize to the earliest DNA replication foci when a cell starts into S-phase (Kennedy et al., 2000) . Perhaps the interaction between pRB and DNMT1 occurs at this stage and is required for the proper initiation and timing of Sphase.
Disruption of epigenetic states in cancer
Cancer is a disease that results from the accumulation and interplay of genetic and epigenetic changes. The disruption of normal methylation patterns, with both hypomethylation and hypermethylation events occurring, is a hallmark of tumorigenesis whose signi®cance is only recently coming to be appreciated . Although, we will focus primarily on the hypermethylation changes, the loss of methylation during tumorigenesis may also be extremely important. To date, however, the signi®cance of hypomethylation in tumorigenesis, which primarily aects the normally methylated parasitic and repetitive DNA sequences, has remained elusive. Several important possible consequences for this hypomethylation are being explored. One concerns the potential that loss of methylation in cancers could induce unwanted expression of the normally repressed transposons scattered throughout the genome leading to deleterious transposition events (Yoder et al., 1997a) . There is evidence that cancer related hypomethylation results in increased expression of some of these elements, but whether this increased expression is harmful to the genome either directly or through transposition of the elements is not clear (Florl et al., 1999) .
Another area of research is focused on whether hypomethylation leads to genomic instability. It has been proposed that DNA methylation, in addition to its repressive eects on transcription, may suppress homologous recombination between repetitive elements in the genome (Colot and Rossignol, 1999) . Work with the fungus Ascobolus immersus, provides evidence that DNA methylation can suppress recombination (Colot et al., 1996) . Increased genomic instability seen in the hypomethylated genome of embryonic stem cells lacking Dnmt1 provides evidence for a genome protective capacity for methylation (Chen et al., 1998) . Furthermore, the pericentromeric areas of many chromosomes are particularly heavily methylated in the constitutive heterochromatin and loss of this pericentromeric methylation both in a genetic disorder, immunode®ciency-centromeric instability-facial anomalies (ICF) syndrome, and through treatment with the demethylating agent 5-aza-2'-deoxycytidine (5aza-dC) is associated with increased chromosome translocations (Ji et al., 1997; Hernandez et al., 1997; Tuck-Muller et al., 2000) . In ICF syndrome, patients harbor mutations in DNMT3B (Keshet et al., 1986; Xu et al., 1999; Hansen et al., 1999; Okano et al., 1999) . Similar patterns of pericentromeric hypomethylation are also seen in multiple types of human cancer (Narayan et al., 1998; Qu et al., 1999) .
Promoter silencing by CpG island hypermethylation
The most emphasized alteration of DNA methylation in cancer is the aberrant hypermethylation of CpG islands surrounding gene promoter regions . The critical issue is that these methylation changes are associated with transcriptional silencing of the involved genes. To date, aberrant CpG island methylation has been shown to be associated with the silencing of a number of classic tumor suppressor genes. In fact, this aberrant silencing can disrupt the expression of genes involved in the fundamental pathways that lead to cancer (Table 1) . Besides these classic tumor suppressor genes, there is an ever increasing list of genes whose corresponding CpG island shows aberrant methylation in cancer (Herman, 1999) . The signi®cance of inactivating some of these genes for tumor progression is not clear, but such events may simply re¯ect a methylation abnormality of cancer cells. While the sites of hypermethylation in cancer already have translational implications for molecular approaches to tumor detection and for therapeutic possibilities , we will stress here two major mechanistic questions currently at the forefront of this ®eld. The ®rst, is how this aberrant CpG island methylation in tumor cells results in silencing? The second, is how aberrant CpG island methylation arises during tumorigenesis?
Mechanisms of promoter silencing by CpG island hypermethylation
The underlying mechanism(s) by which aberrant CpG island methylation contributes to transcriptional repression in tumor cells will almost certainly involve the MBD/HDAC and DNMT/HDAC complexes discussed above in this review. Evidence for the involvement of both DNA methylation and histone deacetylation in silencing tumor suppressor genes in cancer come from studies from our group using inhibitors against HDAC and DNMT activity (Cameron et al., 1999) . Cameron et al. (1999) demonstrated a synergistic eect of an HDAC inhibitor (trichostatin A) and DNMT inhibitor (5-aza-dC) on reactivation of the aberrantly methylated genes p16, TIMP3, and MLH1 in a colon cancer cell line. In this study, treatment with trichostatin A alone did not reactivate the genes, rather the cells ®rst had to be exposed to 5-aza-dC suggesting that the DNA methylation is dominant. This combined treatment must now be considered not only in respect to inhibiting the MBD/HDAC complexes, but now also more directly on the DNMT/HDAC complexes.
The critical evidence for the involvement of methylation and protein complexes attracted to this modi®ca-tion for the transcriptional silencing of hypermethylated genes in cancer lies in demonstrating which speci®c complexes are responsible for the silencing of selected gene promoters. This identi®cation may lead to more elegant and targeted therapeutic approaches to achieve reactivation of speci®c genes.
Establishment of aberrant CpG island methylation during tumorigenesis
The mechanism(s) leading to the development of altered genomic methylation patterns in cancer is not understood. It is not clear whether global hypomethylation and regional CpG island hypermethylation are mechanistically linked. Another unknown is whether aberrant CpG island methylation is the initiating event in gene silencing or if the promoter is silenced by another mechanism and methylation is a secondarỳ lock-down' event. There are probably multiple ways that CpG islands become hypermethylated and silenced during tumorigenesis, but let us consider a model(s) (Figure 4 ) and evidence implicating speci®c events that are potentially involved.
Loss of a CpG island protection factor
As mentioned previously, in embryonic cells the CpG island of the Aprt gene remains methylation free through the binding of a yet unidenti®ed protective trans-acting factor to Sp1 sites near the edge of the island (Macleod et al., 1994; Brandeis et al., 1994; Mummaneni et al., 1995) . Methylation of most of these genes recently reviewed in (Herman, 1999; Baylin and Herman, 2000) . References for the genes not covered by these reviews include; ( Thus, one realistic model that has been proposed to account for aberrant CpG island methylation in cancer is the breakdown in the protection of these islands through loss of such a trans-acting factor. However, direct evidence for this type of mechanism in cancer has been lacking. Cancer cell lines harboring a hypermethylated E-cadherin (E-cad) promoter express an exogenously introduced unmethylated E-cad promoter construct less eciently than cancer cell lines with its endogenous Ecad promoter hypomethylated (Gra et al., 1995) . This result suggests that trans-acting factors needed for full expression of the E-cad promoter are lost in some cancer cells. This loss and the resulting diminished transcriptional capability perhaps in concert with some of the changes discussed below may make this CpG island more susceptible to becoming methylated.
DNMT over-expression in cancer
There is considerable evidence indicating an up regulation of DNMT1 in cancer (Belinsky et al., 1996; Baylin et al., 1998) . However, other reports indicate that there is no correlation between CpG island hypermethylation and DNMT1 levels (Nass et al., 1999; Eads et al., Figure 4 Model for the Epigenetic Silencing of CpG Islands in Cancer. A transcriptionally active CpG island promoter is depicted with positioned nucleosomes, consisting of acetylated (Ac) histone tails, and unmethylated CpG residues (white circles on the black DNA strand). At each end of the CpG island a putative trans-acting factor (Stop signs) protects the CpG island from encroaching methylation. In this model, one or more of the DNMT/HDAC (HD) complexes is proposed to initiate the epigenetic silencing of the CpG island.
(1) DNMT/HDAC complexes gain access to the CpG island and begin to transcriptionally silence (X) the region by methylating CpG sites (grey circles) and deacetylating the histones. Events leading to this possibly include one but probably more of the following: loss of the trans-acting protective factor, elevation in DNMT(s) levels, and/or disregulation of the DNMT(s) causing mistargeting of the DNMT/HDAC complex either through loss of a interacting factor (e.g. Rb or DMAP1 for DNMT1) or gain of a targeting factor through illegitimate expression (e.g. embryonic factor). (2) This initial silencing may then predispose this CpG island to replicate later in S-phase where the DNMT1/HDAC2/DMAP1 heterochromatin inheritance machinery will further facilitate this conversion. The DNMT1/HDAC2/DMAP1 complex is bound to PCNA near the replication fork with only one strand of newly synthesized chromatin is illustrated for simplicity (dashed line represents the other). (3) Alternatively, the potential deregulation of replication during tumorigenesis (perhaps through loss of the Rb pathway) exposes the transcriptionally active CpG island to the DNMT1 complex either through slippage to a late S-phase replication timing or deregulation of the machinery leading to methylation and histone deacetylation events that silence transcription. (4) The progressive methylation of the CpG island will then allow MBD complexes (including HDACs and chromatin remodeling machinery`CR') to bind and assist in the progression to a late replicating hypermethylated/hypoacetylated transcriptionally incompetent state 1999). Experimental evidence indicates that forced overexpression of the murine Dnmt1 gene in NIH3T3 cells results in cellular transformation (Wu et al., 1993) . In human ®broblasts, sustained over-expression of DNMT1 leads to the processive time-dependent hypermethylation of a number of CpG islands . The DNMT1 gene is upregulated in response to fos over-expression and appears to play a role in the fos induced cell transformation (Bakin and Curran, 1999) . Conversely, reduction of DNMT1 levels appears to have protective eects. Mice predisposed to colonic polyp formation (Min mice) develop fewer polyps in a Dnmt1 heterozygous background and also when treated with 5aza-dC (Laird and Jaenisch, 1996) . Reduction of DNMT1 through an antisense approach blocked tumorigenesis (MacLeod and Szyf, 1995; Ramchandani et al., 1997) . Interestingly, deletion of the DNMT1 gene in a colon cancer cell line (HCT116), while resulting in slower growth, diminished genomic methylation levels only modestly (*20%) (Rhee et al., 2000) . In particular, aberrant CpG island methylation was retained suggesting that another methyltransferase(s) maintains this methylation. Like DNMT1, the more recently described DNMT3A and DNMT3B enzymes also appear to be modestly over-expressed in cancer and therefore, the balance of all three enzymes and their accumulative and coordinated eects must be studied (Xie et al., 1999; Robertson et al., 1999) .
Disruption or mistargeting of a DNMT complex
Another potential factor, perhaps in conjunction with the modest increase in DNMT levels, is the deregulation or mistargeting of the enzymatic or repression properties of these enzymes. The deregulation could be due to the loss of one or more of the factors that complex with the DNMTs (e.g. pRb, DMAP1, TSG101). The cell cycle control Rb pathway is disrupted in almost every cancer; therefore, we must consider the implications of the disruption of the DNMT1/pRB interaction on the methylation abnormalities that arise in cancer. In addition, the Dmap1 gene maps to a methylation modi®er locus (MEMO1) on the short arm of chromosome 1 (MR Rountree, KE Bachman and SB Baylin, unpublished results) in a region of frequent LOH in a number of cancers. LOH of the MEMO1 locus correlates with methylation abnormalities at the class I major histocompatibility complex gene cluster in neuroblastoma cell lines (Cheng et al., 1996a,b) . We have found additional methylation abnormalities, both hypo-and hypermethylation events, associated with Neuroblastoma cell lines with LOH of this region (MR Rountree, KE Bachman and SB Baylin, unpublished results). It is not clear whether DMAP1 is the MEMO1 locus, but it has to be considered the top candidate. Many other cancers have LOH of this region and it will be interesting to see if certain methylation abnormalities correlate with this loss. In addition, because additional 5' coding sequences were only recently identi®ed (Yoder et al., 1996; Gaudet et al., 1998) , the DNMT1 overexpression experiments described above were conducted with a form of DNMT1 which lacks the ®rst 118 amino acid found normally in somatic cells (Wu et al., 1993; Vertino et al., 1996) . This missing portion contains the DMAP1 binding region and, therefore, the exogenously expressed DNMT1 could not have interacted with DMAP1 and this fact must now be considered as contributing to these experimental results.
Disruption of Replication Timing
As described early in our review, duplication of the genome occurs through spatial and temporal patterns during the course of S-phase progression. The DNMT1 complex that is modulated dierentially during dierent portions of S-phase progression is emerging as an important component in the perpetuation of chromatin states during this process (Rountree et al., 2000) . Thus, we should consider cancer related methylation abnormalities in this context. The global hypomethylation seen in many cancers begs for a mechanism that is global in nature. Could S-phase abnormalities aect methylation patterns by altering the replication timing of sequences? Alteration in the spatial and temporal patterns of replication could expose sequences to replication and chromatin formation machinery with which they do not normally interact. For example, certain regions of the genome might fail to become normally methylated and transcriptionally repressed because of replication timing errors that prevent the proper targeting of DNA methylation and chromatin formation complexes. Similarly, and critical for the emphasis of this review, CpG islands might become aberrantly methylated via replication timing errors that shift these regions to late S-phase and allow exposure to DNA methylation and chromatin formation machinery that promotes transcriptionally incompetent chromatin formation.
To form credible hypotheses regarding the above replication events, we must ®rst ask whether cancer cells have the types of S-phase abnormalities that may be involved. Kennedy et al. (2000) recently demonstrated that the earliest observed replication foci in normal cells surround the nucleolus and contain pRB and its family members as well as E2F. In addition, recent studies indicate that a pRB-SWI/SNF interaction is necessary for proper S-phase progression (Harbour and Dean, 2000a,b) . Furthermore, a very signi®cant observation made by Kennedy et al. (2000) was that these earliest replication foci are not present in immortalized cells. Thus, the immortilization process, perhaps through altered targeting of pRB, may result in changes in the spatial organization of replication. It is likely that cancer cells have similar defects, if not even more severe ones. Evidence for replication timing errors in cancer comes from studies demonstrating a more asynchronous replication timing for homologous loci in malignant cells compared to their normal counterparts (Amiel et al., 1998a (Amiel et al., ,b, 1999 . Certainly, further work will be required to test whether replication abnormalities can initiate and propagate methylation abnormalities during tumorigenesis. How-ever, this area seems a rich one to study for potentially understanding the genesis of abnormal DNA methylation and chromatin patterns in cancer cells.
Summary
In this review, we have discussed the rapidly emerging recognition that synergy between heritable formation of chromatin, especially the role of histone deacetylation in this process, and the establishment of DNA methylation, is a critical aspect of maintaining normal domains of transcriptional repression throughout the genome of mammalian cells. Critical to this process is our understanding of how these events are coordinated with timing of DNA replication and cell cycle events. Alterations in patterns of both chromatin formation and DNA methylation are fundamental to abnormalities of key gene expression in cancer. The potentially reversible nature of these cancer changes makes an ever-deepening understanding of the basic mechanisms underlying them an important goal of future research.
